Organon & Co.
OGN
Classificação em ações
#4348
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Preço da ação
$13.76
Última sincronização: 2026-10-20
Valor de mercado
$3.61B
Variação (1 dia)
0.07%
Variação (1 ano)
52.49%
País
US
Negociar Organon & Co. (OGN)
Categoria
Healthcare
Receita da Organon & Co. (OGN)
Receita em Jun 2026 TTM: $6.13B
De acordo com os últimos relatórios financeiros da Organon & Co., a receita atual da empresa (TTM) é $6.13B. Em 2024, a empresa obteve uma receita de $6.40B um aumento em relação a a receita do ano 2023, que foi de $6.26B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Organon & Co. de 2017 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $6.13B | -1.43% |
| 2025 | $6.22B | -2.92% |
| 2024 | $6.40B | 2.24% |
| 2023 | $6.26B | 1.44% |
| 2022 | $6.17B | -2.06% |
| 2021 | $6.30B | -3.49% |
| 2020 | $6.53B | -16.01% |
| 2019 | $7.78B | -20.46% |
| 2018 | $9.78B | -6.89% |
| 2017 | $10.50B | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $79.67B | 1,200.24% |
US
|
|
| $99.34B | 1,521.27% |
US
|
|
| $64.39B | 950.86% |
US
|
|
| $66.40B | 983.73% |
US
|
|
| $77.52B | 1,165.20% |
CH
|
